Publications by authors named "D Strippoli"
(1) Background/Objectives: Nail psoriasis (NP) is a chronic and difficult-to-treat disease, which causes significant social stigma and impairs the patients' quality of life. Moreover, nail psoriasis is a true therapeutic challenge for clinicians. The presence of nail psoriasis can be part of a severe form of psoriasis and can have predictive value for the development of psoriatic arthritis.
View Article and Find Full Text PDFIntroduction: Guselkumab, a human monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23), has shown efficacy in psoriasis and psoriatic arthritis. However, long-term real-world data on its effectiveness in patients with inadequate response to ustekinumab are limited. This study investigates guselkumab's long-term effectiveness and safety in patients with psoriasis with partial response to ustekinumab.
View Article and Find Full Text PDFComparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study - IL PSO (Italian landscape psoriasis).
J Dermatolog Treat
December 2024
Purpose: Tildrakizumab is a selective inhibitor of IL-23 approved for the treatment of moderate-to-severe plaque psoriasis in two dosages. We conducted a 16-week multicenter retrospective study to compare the effectiveness and safety of tildrakizumab 200 mg versus tildrakizumab 100 mg in patients with a high disease burden or high body weight.
Materials And Methods: Our retrospective study included 134 patients treated with tildrakizumab 200 mg and 364 patients treated with tildrakizumab 100 mg from 28 Italian Dermatology Units affected by moderate-to-severe plaque psoriasis.
Long-term proactive management of psoriasis with calcipotriol and betamethasone dipropionate foam: an Italian consensus through a combined nominal group technique and Delphi approach.
Int J Dermatol
December 2022
Article Synopsis
- Long-term management of psoriasis is crucial but challenging; the PSO-LONG trial showed that a combination treatment of betamethasone dipropionate and calcipotriol foam, applied twice a week for a year, can reduce relapses but still needs further investigation for long-term use.
- In the ProActive Management (PAM) program, experts reached consensus on 14 out of 18 statements, recognizing the importance of proactive topical treatments to minimize relapse risk, especially for resistant disease sites or when other therapies are not suitable.
- Establishing proactive strategies in treatment guidelines is seen as vital for improving the management of mild to moderate psoriasis, while more research on patient adherence is necessary.